These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 33416933)
1. Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? Bahadoram M; Keikhaei B; Saeedi-Boroujeni A; Mahmoudian-Sani MR Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):997-1001. PubMed ID: 33416933 [TBL] [Abstract][Full Text] [Related]
2. Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19. Manayi A; Nabavi SM; Khayatkashani M; Habtemariam S; Khayat Kashani HR Mol Biol Rep; 2021 Dec; 48(12):8221-8225. PubMed ID: 34655016 [TBL] [Abstract][Full Text] [Related]
3. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Zhao N; Di B; Xu LL Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243 [TBL] [Abstract][Full Text] [Related]
4. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881 [TBL] [Abstract][Full Text] [Related]
5. The Antimalarial Chloroquine Suppresses LPS-Induced NLRP3 Inflammasome Activation and Confers Protection against Murine Endotoxic Shock. Chen X; Wang N; Zhu Y; Lu Y; Liu X; Zheng J Mediators Inflamm; 2017; 2017():6543237. PubMed ID: 28321151 [TBL] [Abstract][Full Text] [Related]
6. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches. Ram C; Jha AK; Ghosh A; Gairola S; Syed AM; Murty US; Naidu VGM; Sahu BD Eur J Pharmacol; 2020 Oct; 885():173503. PubMed ID: 32858047 [TBL] [Abstract][Full Text] [Related]
7. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Saeedi-Boroujeni A; Mahmoudian-Sani MR; Nashibi R; Houshmandfar S; Tahmaseby Gandomkari S; Khodadadi A Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):247-258. PubMed ID: 34015982 [TBL] [Abstract][Full Text] [Related]
8. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. Lucchesi A; Silimbani P; Musuraca G; Cerchione C; Martinelli G; Di Carlo P; Napolitano M J Med Virol; 2021 Jan; 93(1):124-126. PubMed ID: 32579244 [No Abstract] [Full Text] [Related]
9. Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Tang TT; Lv LL; Pan MM; Wen Y; Wang B; Li ZL; Wu M; Wang FM; Crowley SD; Liu BC Cell Death Dis; 2018 Mar; 9(3):351. PubMed ID: 29500339 [TBL] [Abstract][Full Text] [Related]
11. NLRP3 Inflammasome-Mediated Inflammation in Acute Pancreatitis. Ferrero-Andrés A; Panisello-Roselló A; Roselló-Catafau J; Folch-Puy E Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751171 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Zhang W; Qin C; Fei Y; Shen M; Zhou Y; Zhang Y; Zeng X; Zhang S Clin Immunol; 2022 Jun; 239():109022. PubMed ID: 35477027 [TBL] [Abstract][Full Text] [Related]
13. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861 [TBL] [Abstract][Full Text] [Related]
14. Non-coding RNAs: The key regulators in NLRP3 inflammasome-mediated inflammatory diseases. Feng X; Luo D; Wei G; Zhan F; Hua F; Xu G Int Immunopharmacol; 2021 Nov; 100():108105. PubMed ID: 34481143 [TBL] [Abstract][Full Text] [Related]
15. Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients. Cassone A; Iacoviello L; Cauda R Future Microbiol; 2020 Oct; 15():1523-1526. PubMed ID: 33206554 [No Abstract] [Full Text] [Related]
16. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. Richard SA; Kampo S; Hechavarria ME; Sackey M; Buunaaim ADB; Kuugbee ED; Anabah TW J Immunol Res; 2020; 2020():4582612. PubMed ID: 33062720 [TBL] [Abstract][Full Text] [Related]
17. Chloroquine and its derivatives in the management of COVID-19: A scoping review. Pimentel J; Andersson N Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192 [TBL] [Abstract][Full Text] [Related]
18. Role of NLRP3 inflammasome in inflammatory bowel diseases. Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674 [TBL] [Abstract][Full Text] [Related]
19. Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Kiedrowski M; Kapala P; Kiedrowska M; Skoczynska A; Czerw A; Deptała A Med Hypotheses; 2021 Jan; 146():110434. PubMed ID: 33277106 [TBL] [Abstract][Full Text] [Related]
20. Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19. Ahmad B; Ul Hassan N; Sehar B; Zeb F; E Nayab D; Siddiqui FA Clin Med Res; 2021 Dec; 19(4):179-182. PubMed ID: 34933950 [No Abstract] [Full Text] [Related] [Next] [New Search]